Insights

Innovative Diagnostic Technology Anavasi Diagnostics has developed proprietary, rapid, and precise COVID-19 testing solutions that can deliver results within 30 minutes, offering a significant advantage over traditional PCR testing. This technology positions the company well for expanding into other infectious disease diagnostics, creating multiple sales opportunities in healthcare and laboratory markets.

Emergency Authorization Leverage The company's tests are currently authorized for emergency use by the FDA, which may present opportunities to collaborate with healthcare providers and laboratories seeking quick deployment of COVID-19 diagnostic tools, especially during ongoing or future public health crises.

Growing Team & Leadership Recent hiring of a Vice President of Sales & Marketing signals a focus on business expansion and market penetration, opening potential sales channels through targeted outreach to healthcare institutions, government agencies, and distribution partners.

Medium-Scale Revenue & Funding With revenues between $1M and $10M and an initial funding of $2.6M, Anavasi is poised for growth, providing opportunities for sales partnerships in distribution, OEM collaborations, or licensing to accelerate market reach and increase sales volume.

Market Positioning & Future Growth As a player focused on point-of-care diagnostics with aspirations to expand beyond COVID-19, Anavasi offers potential for strategic partnerships in expanding into other disease testing markets, making it a promising target for sales channels aligned with innovative healthcare solutions.

Anavasi Diagnostics® Tech Stack

Anavasi Diagnostics® uses 8 technology products and services including Squarespace, Open Graph, Cart Functionality, and more. Explore Anavasi Diagnostics®'s tech stack below.

  • Squarespace
    Content Management System
  • Open Graph
    Content Management System
  • Cart Functionality
    E-commerce
  • Squarespace Commerce
    E-commerce
  • Google Fonts API
    Font Scripts
  • Stimulus
    Javascript Frameworks
  • Choices
    Javascript Libraries
  • HSTS
    Security

Anavasi Diagnostics®'s Email Address Formats

Anavasi Diagnostics® uses at least 1 format(s):
Anavasi Diagnostics® Email FormatsExamplePercentage
First.Last@anavasidx.comJohn.Doe@anavasidx.com
50%
First.Last@anavasidx.comJohn.Doe@anavasidx.com
50%

Frequently Asked Questions

What is Anavasi Diagnostics®'s official website and social media links?

Minus sign iconPlus sign icon
Anavasi Diagnostics®'s official website is anavasidx.com and has social profiles on LinkedInCrunchbase.

What is Anavasi Diagnostics®'s NAICS code?

Minus sign iconPlus sign icon
Anavasi Diagnostics®'s NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Anavasi Diagnostics® have currently?

Minus sign iconPlus sign icon
As of January 2026, Anavasi Diagnostics® has approximately 10 employees across 1 continents, including North America. Key team members include Director, Corporate Strategy And Planning: D. P.. Explore Anavasi Diagnostics®'s employee directory with LeadIQ.

What industry does Anavasi Diagnostics® belong to?

Minus sign iconPlus sign icon
Anavasi Diagnostics® operates in the Medical Equipment Manufacturing industry.

What technology does Anavasi Diagnostics® use?

Minus sign iconPlus sign icon
Anavasi Diagnostics®'s tech stack includes SquarespaceOpen GraphCart FunctionalitySquarespace CommerceGoogle Fonts APIStimulusChoicesHSTS.

What is Anavasi Diagnostics®'s email format?

Minus sign iconPlus sign icon
Anavasi Diagnostics®'s email format typically follows the pattern of First.Last@anavasidx.com. Find more Anavasi Diagnostics® email formats with LeadIQ.

How much funding has Anavasi Diagnostics® raised to date?

Minus sign iconPlus sign icon
As of January 2026, Anavasi Diagnostics® has raised $2.6M in funding. The last funding round occurred on Jan 12, 2022 for $2.6M.

When was Anavasi Diagnostics® founded?

Minus sign iconPlus sign icon
Anavasi Diagnostics® was founded in 2020.

Anavasi Diagnostics®

Medical Equipment ManufacturingWashington, United States2-10 Employees

We are experienced scientists, engineers, and business people working together to tackle a global challenge: detecting infection with COVID-19. Together, we are determined to help save lives by delivering rapid, precise, and inexpensive diagnostic tests.   

Our goal is to enable health care professionals to confidently provide lab-quality results in minutes instead of days so that patients can confidently know almost immediately whether they are positive -- or not. 

Our first product, The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector, is designed to provide a precise diagnosis of COVID-19 in under 30-minutes (on average) instead of the 1-3 days that most testing services and physician offices now require for PCR testing. 

Using our patent-pending proprietary technologies, the AscencioDx diagnostic test is administered painlessly, in just seconds, with a lower-nasal swab.

Our mission is to continue developing and marketing diagnostic test systems for diseases in addition to COVID-19 using our PCR- equivalent point-of-care diagnostic platform without the unnecessary delay, expense, or reliance on less-than-precise antigen testing. 

This is only the beginning.

*The AscencioDx® Covid-19 Test and The AscencioDx® Molecular Detector have not been FDA cleared or approved, but have been authorized for emergency use by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

Section iconCompany Overview

NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2020
Employees
2-10

Section iconFunding & Financials

  • $2.6M

    Anavasi Diagnostics® has raised a total of $2.6M of funding over 3 rounds. Their latest funding round was raised on Jan 12, 2022 in the amount of $2.6M.

  • $1M$10M

    Anavasi Diagnostics®'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $2.6M

    Anavasi Diagnostics® has raised a total of $2.6M of funding over 3 rounds. Their latest funding round was raised on Jan 12, 2022 in the amount of $2.6M.

  • $1M$10M

    Anavasi Diagnostics®'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.